0
0
Cuba reports an important success in the fight against coronavirus. A new vaccine surpasses the efficacy of the recently introduced preparation. It is on par with the Biontech preparation, raising hopes on the island.
The vaccine candidate Abdala, developed in Cuba, has an efficacy of more than 90 percent against the coronavirus, according to the state-owned pharmaceutical company Biocubafarma. With three doses of vaccine, the efficacy is 92.28 percent, the company said. The study involved 48,010 volunteers between the ages of 19 and 80. The three doses were administered 14 days apart and controlled with placebos, it said.
A second Cuban vaccine candidate, the preparation Soberana 2, has 62 percent efficacy after two of the planned three doses of vaccine, according to the manufacturer Finlay. Finlay CEO Vicente Cruz had said he expected the vaccine to be even more effective after the third dose. Both vaccines are expected to be licensed in Cuba soon.
This would make them the first Corona vaccines developed and manufactured in Latin America to reach the market. The study results will be evaluated by an independent panel of experts. However, no assessment has yet been received from independent authorities such as the European Medicines Agency (EMA) – this would have to be requested by the Cuban state, which is not currently expected.
— source:orf.at/ntv.de/picture: pixabay.com
This post has already been read 845 times!
